Interactions on record — worth a quick check against your medications. Based on 2 of 5 ingredients. Check your meds →
Dietary supplement

Extra Soy Lecithin Ingredients & Drug Interactions

by CATALO

Softgel Capsule Category: Botanical With Nutrients
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Extra Soy Lecithin is a dietary supplement by CATALO with 5 active ingredients. Its ingredients are commonly taken for replacing fluids and electrolytes, preventing dehydration during exercise or illness, treating low blood sodium (under medical care).Based on those ingredients, 205 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Sodium. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Extra Soy Lecithin by CATALO

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

CATALO Extra Soy Lecithin contains 2 active ingredients: sodium and soy lecithin (natural). The product also contains gelatin, a humectant, and purified water as inactive ingredients.

Soy lecithin is a natural phospholipid that comes from soybean oil; sodium is an essential electrolyte. Neither ingredient is a vitamin or mineral isolate in the traditional sense—soy lecithin is added for its phospholipid content, and sodium is present at levels that need to be monitored if you're taking certain medications.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: heart health, memory and brain support.
  • We looked for evidence on: Hyperlipidemia, Congestive heart failure, Age-related cognitive decline, liver health, blood pressure regulation, cholesterol management.
  • The closest evidence on file: Lecithin is rated "Insufficient Reliable Evidence To Rate" for Age-related cognitive decline (Natural Medicines).
  • Also on file: Lecithin is rated "Insufficient Reliable Evidence To Rate" for Hyperlipidemia.
  • Also on file: Sodium is rated "Insufficient Reliable Evidence To Rate" for Congestive heart failure.

The evidence here is mixed and limited. Sodium may be likely effective for cystic fibrosis and possibly effective for amphotericin B kidney damage, but there isn't enough reliable evidence to rate it for bipolar disorder or congestive heart failure.

Soy lecithin (lecithin) is likely ineffective for Alzheimer disease; for age-related mental decline, anxiety, bipolar disorder, and fatty liver from intravenous nutrition, the evidence is too limited to rate. If you're considering this product for a specific condition, talk with your doctor or pharmacist—the data doesn't show it's a proven treatment for most uses.

The evidence, ingredient by ingredient Sodium Lecithin

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Sodium is well tolerated in normal dietary amounts (up to about 2.3 grams daily), but too much is tied to high blood pressure and strain on the heart. This product is a sodium supplement, so it's not meant for everyday eating—avoid it if you're on a salt-restricted diet or have high blood pressure unless your doctor says it's okay.

Soy lecithin is generally well tolerated and likely safe in pregnancy and lactation; sodium is rated likely safe in pregnancy but possibly unsafe during breastfeeding, so if you're nursing, check with your doctor or pharmacist first. Lecithin can cause abdominal pain, diarrhea, nausea, and bloating in some people, and it may trigger allergic skin reactions if you have a soy or egg allergy.

Side effects, ingredient by ingredient Sodium Lecithin

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 2 matched ingredients can interact with medications — Sodium.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: lithium.
  • For scale: 205 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before you take this product, double-check with your doctor or pharmacist if you're on lithium, any blood pressure medication, corticosteroids (such as prednisone or hydrocortisone), didanosine, sodium phosphate bowel prep, tolvaptan, or any other sodium-containing drug. All of these are moderately affected by extra sodium intake.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

This product is a sodium supplement, so it's for specific medical situations—not routine use. If you take blood pressure medication, lithium, corticosteroids, or any sodium-containing drug, you need to check with your doctor or pharmacist before starting it.

Soy lecithin itself appears well tolerated and has no known drug interactions, but the sodium content is the real consideration here. Your own healthcare provider can tell you whether this product fits your situation.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 22, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Extra Soy Lecithin, straight from the product label.

Brand CATALO
Net contents 45 Softgel(s)
Market status On market
Date entered into DSLD Feb 22, 2024
DSLD ID 303081
Product type Botanical With Nutrients
Supplement form Softgel Capsule
Dietary claims / uses Nutrient, All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Children (All), Pregnant Women, Lactating
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Extra Soy Lecithin by CATALO, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Softgel(s)
Maximum serving Sizes:
2 Softgel(s)
Servings per container
22
IngredientAmount% DV
Sodium0.5 mg--
Carbohydrates0.1 Gram(s)--
Energy19 Kcal(s)--
Total Fat1.7 Gram(s)--
Saturated Fat0.3 Gram(s)--
Trans Fat0 Gram(s)--
Protein0 Gram(s)--
Sugars0 Gram(s)--
Soy Lecithin, Natural2400 mg--

Other ingredients: Gelatin, Humectant, Water, Purified

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Blood vessel cleanser For heart & cardiovascular health Support memory & brain activities

Main functions: May assist in stabilizing blood pressure, blood lipids, cholesterol and maintaining cardiovascular health Enhance brain activities, memory and concentration Improve liver health and maintain healthy liver functions Improve liver detoxification and alcohol breakdown

Enhance memory & brain activities Improve liver health High concentration of phosphatides

Made in USA

FDA Statement of Identity

Dietary Supplement

Dietary Supplement

Formula

CATALO Extra Soy Lecithin is made from soybeans by special technology to provide a high concentration of phosphatides which is easily absorbed by the body and thus improves its efficacy. Extra Soy Lecithin provides basic structural components of cells in brain, liver and other parts of the body. Also named "blood vessels cleanser" as it may assist in stabilizing blood pressure, blood lipid and cholesterol, maintaining blood vessel elasticity and heart health. Extra Soy Lecithin also enhances brain activities, memory and concentration. It can further improve liver health, maintain healthy liver functions, such as detoxification and alcohol breakdown, as well as the revitalization of overall health. It is suitable for people of all ages.

Suitable for: Adults, children, pregnant and lactating women, frequently diners-out, frequent meaty or greasy diet, promote liver functions and enhance memory, concern about cardiovascular and liver health, suitable for people concerned about blood pressure, blood lipids and cholesterol

Suggested/Recommended/Usage/Directions

Serving directions For adults, take 1-2 softgels twice daily. For children, take 1 softgel daily. For children, take 1 softgel daily. For pregnant and lactating women, take 2 softgels twice daily. Take after meal

Storage

Storage Keep in a dry and cool place. Avoid direct sunlight

General Statements

Net weight 78.9g (1754mg x 45 softgels)

Seals/Symbols

Certified Good Manufacturing Practices cGMP

Precautions

Contains Soy.

See for yourself

Extra Soy Lecithin by CATALO label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Extra Soy Lecithin by CATALO

These are the 5 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Softgel(s) Dosage formSoftgel Capsule Servings per container22 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Sodium

Interacts with
205 drugs
0.5 mg per serving

Sodium is an essential mineral and electrolyte your body needs to balance fluids, support nerves, and help muscles work. Most people in modern diets g...

Sodium monograph & interactions

Carbohydrates

0.1 Gram(s) per serving

Energy

19 Kcal(s) per serving

Protein

0 Gram(s) per serving

Soy Lecithin, Natural

No known
interactions
2400 mg per serving Form: Phosphatides

Lecithin is a natural fatty substance found in foods and made by the body that is widely used as a supplement and food emulsifier. Evidence supporting...

Soy Lecithin, Natural monograph & interactions

Other (inactive) ingredients: Gelatin, Humectant, Water, Purified. These complete the product’s ingredient list but are not active constituents.

Interaction report

Extra Soy Lecithin by CATALO Drug Interactions

Want to check YOUR meds against Extra Soy Lecithin?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
205Drugs
205 Moderate

Ingredients driving the most interactions

Sodium 205

Each ingredient & the kinds of drugs it affects

For each ingredient in Extra Soy Lecithin with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Sodium7 drug types · 205 drugs

Antihypertensive Drugs

Theoretically, a high intake of dietary sodium might reduce the effectiveness of antihypertensive drugs.
High intake of dietary sodium can increase systolic and diastolic blood pressure. Also, high intake of sodium may necessitate increased use of antihypertensive medications to achieve blood pressure control in some patients, such as those with chronic kidney disease.

Likelihood Probable Evidence A
Corticosteroids

Concomitant use of mineralocorticoids and some glucocorticoids with sodium supplements might increase the risk of hypernatremia.
Mineralocorticoids and some glucocorticoids (corticosteroids) cause sodium retention. This effect is dose-related and depends on mineralocorticoid potency. It is most common with hydrocortisone, cortisone, and fludrocortisone, followed by prednisone and prednisolone.

Likelihood Possible Evidence D
Didanosine (Videx)

Concomitant use of didanosine with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia.
Didanosine formulations contain a significant amount of sodium.

Likelihood Probable Evidence C
Lithium

Altering dietary intake of sodium might alter the levels and clinical effects of lithium.
High sodium intake can reduce plasma concentrations of lithium by increasing lithium excretion. Reducing sodium intake can significantly increase plasma concentrations of lithium and cause lithium toxicity in patients being treated with lithium carbonate. Stabilizing sodium intake is shown to reduce the percentage of patients with lithium level fluctuations above 0.8 mEq/L. Patients taking lithium should avoid significant alterations in their dietary intake of sodium.

Likelihood Probable Evidence B
Sodium Phosphates

Theoretically, concomitant use of sodium phosphate with sodium supplements might increase the risk of hypernatremia.
Use of high doses (> 45 mL in 24 hours) of sodium phosphate, such as those used for bowel cleansing before surgery, can lead to serious electrolyte disturbances, including hypernatremia. The risk of hypernatremia is highest in the elderly and people with other risk factors for electrolyte disturbances.

Likelihood Possible Evidence D
Sodium-Containing Drugs

Concomitant use of sodium-containing drugs with additional sodium from dietary or supplemental sources may increase the risk of hypernatremia and long-term sodium-related complications.
The Chronic Disease Risk Reduction (CDRR) intake level of 2.3 grams of sodium daily indicates the intake at which it is believed that chronic disease risk increases for the apparently healthy population. Some medications contain high quantities of sodium. When used in conjunction with sodium supplements or high-sodium diets, the CDRR may be exceeded. Additionally, concomitant use may increase the risk for hypernatremia; this risk is highest in the elderly and people with other risk factors for electrolyte disturbances.

Likelihood Possible Evidence D
Tolvaptan (Samsca)

Theoretically, concomitant use of tolvaptan with sodium might increase the risk of hypernatremia.
Tolvaptan is a vasopressin receptor 2 antagonist that is used to increase sodium levels in patients with hyponatremia. Patients taking tolvaptan should use caution with the use of sodium salts such as sodium chloride.

Likelihood Probable Evidence C
The maker

Brand information

Manufacturer and brand details for Extra Soy Lecithin, from the product label.

CATALO

See all CATALO products
Name
CATALO Natural Health Foods
Street Address
5/F, Suite C-D, 15 Cheung Shun St.
City
Hong Kong
Phone Number
(852) 3556 8686
Web Address
CATALO.com
Pharmacist Counseling Corner

Extra Soy Lecithin by CATALO: Common Questions

Does Extra Soy Lecithin by CATALO interact with any medications?
Yes. Based on its ingredients, Extra Soy Lecithin has a known interaction with 205 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Extra Soy Lecithin contains 5 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this if I have high blood pressure?
Not without checking with your doctor first. Sodium can reduce how well blood pressure medications work, so extra sodium from a supplement may make it harder to control your pressure. Your doctor can tell you whether it's right for you.
What does soy lecithin do?
Soy lecithin is a natural phospholipid extracted from soybean oil. The facts we hold show it's likely ineffective for Alzheimer disease and don't establish strong evidence for the other uses listed. Talk with your pharmacist or doctor about what you're hoping to treat.
Is this safe if I'm pregnant or breastfeeding?
Soy lecithin is likely safe in both pregnancy and lactation. Sodium is likely safe in pregnancy but rated possibly unsafe during breastfeeding, so if you're nursing, discuss it with your doctor or pharmacist before taking it.
What side effects does soy lecithin cause?
Soy lecithin is well tolerated overall, but it can cause abdominal pain, diarrhea, nausea, and bloating in some people. If you have a soy or egg allergy, it may trigger an allergic skin reaction.
I take lithium for bipolar disorder. Can I use this?
No—not without your psychiatrist's and pharmacist's involvement. Sodium affects how your body handles lithium; high sodium intake lowers lithium levels, and low sodium intake raises them to dangerous levels. You need professional guidance here.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Extra Soy Lecithin is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Extra Soy Lecithin label
Sources

Sources & How We Checked

Extra Soy Lecithin's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 47 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Sodium 38 references
  1. Garabedian-Ruffalo SM, Ruffalo RL. Drug and nutrient interactions. Am Fam Physician 1986;33:165-74.
  2. Food and Drug Administration Science Background: Safety of Sodium Phosphates Oral Solution. September 17, 2001. Available at: http://www.fda.gov/cder/drug/safety/sodiumphospate.htm
  3. Coton T, Mallaret C, Coilliot C, Carre D, Guisset M. Severe acute ulcerated gastritis induced by salt. Presse Med 2009;38(3):499-500. PubMed
  4. Frings-Meuthen P, Buehlmeier J, Baecker N, et al. High sodium chloride intake exacerbates immobilization-induced bone resorption and protein losses. J Appl Physiol 2011;111(2):537-542. PubMed
  5. Frings-Meuthen P, Baecker N, Heer M. Low-grade metabolic acidosis may be the cause of sodium chloride-induced exaggerated bone resorption. J Bone Miner Res 2008;23(4):517-524. PubMed
  6. Alam S, Johnson AG. A meta-analysis of randomised controlled trials (RCT) among healthy normotensive and essential hypertensive elderly patients to determine the effect of high salt (NaCl) diet of blood pressure. J Hum Hypertens 1999;13(6):367-74.
  7. Boudville N, Ward S, Benaroia M, House AA. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 2005;18(10):1300-5. PubMed
  8. Bennett WM. Drug interactions and consequences of sodium restriction. Am J Clin Nutr 1997;65(2 Suppl):678S-681S. PubMed
  9. Okusa MD, Crystal LJ. Clinical manifestations and management of acute lithium intoxication. Am J Med 1994;97(4):383-9. PubMed
  10. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academy Press, 2005. Available at: http://www.nap.edu/openbook.php?record_id=10925. DOI
  11. D'Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr 2012;31(4):489-98. PubMed
  12. Goldsmith SR. Hyponatremia in heart failure: time for a trial. J Card Fail 2013;19(6):398-400. PubMed
  13. Willocks L, Brettle R, Keen J, Valentine C, Pinching AJ. Formulations of didanosine (ddI) and salt overload. Lancet 1992;339(8786):190.
  14. Chen L, Zhang Z, Chen W, Whelton PK, Appel LJ. Lower Sodium Intake and Risk of Headaches: Results From the Trial of Nonpharmacologic Interventions in the Elderly. Am J Public Health. 2016;106(7):1270-5. PubMed
  15. Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced cardiovascular risk. Circulation. 2014;129(9):981-9. PubMed
  16. Cook NR, Appel LJ, Whelton PK. Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention. J Am Coll Cardiol. 2016;68(15):1609-1617. PubMed
  17. Mente A, O'Donnell M, Rangarajan S, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet. 2016;388(10043):465-75. PubMed
  18. Moosavian SP, Haghighatdoost F, Surkan PJ, Azadbakht L. Salt and obesity: a systematic review and meta-analysis of observational studies. Int J Food Sci Nutr. 2017;68(3):265-277. PubMed
  19. O'Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371(7):612-23. DOI
  20. Poggio R, Gutierrez L, Matta MG, Elorriaga N, Irazola V, Rubinstein A. Daily sodium consumption and CVD mortality in the general population: systematic review and meta-analysis of prospective studies. Public Health Nutr. 2015;18(4):695-704. PubMed
  21. Stallings VA, Harrison M, Oria M; Committee to Review the Dietary Reference Intakes for Sodium and Potassium, Food and Nutrition Board, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Washington (DC): National Acad
  22. Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced Salt Intake for Heart Failure: A Systematic Review. JAMA Intern Med. 2018 Dec 1;178(12):1693-1700. PubMed
  23. Yancy CW. Sodium Restriction in Heart Failure: Too Much Uncertainty-Do the Trials. JAMA Intern Med. 2018 Dec 1;178(12):1700-1701. PubMed
  24. He FJ, Campbell NRC, Ma Y, MacGregor GA, Cogswell ME, Cook NR. Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship with mortality: implications for public health. Int J Epidemiol. 2018;47(6):1784-1795. PubMed
  25. Murthy K, Ondrey GJ, Malkani N, et al. THE EFFECTS OF HYPONATREMIA ON BONE DENSITY AND FRACTURES: A SYSTEMATIC REVIEW AND META-ANALYSIS. Endocr Pract. 2019;25(4):366-378. PubMed
  26. Messerli FH, Hofstetter L, Syrogiannouli L, et al. Sodium intake, life expectancy, and all-cause mortality. Eur Heart J 2021;42(21):2103-2112. PubMed
  27. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2020;12(12):CD004022. PubMed
  28. Giatti S, Santos RB, Aielo AN, et al. Association of sodium with obstructive sleep apnea. The ELSA-Brasil study. Ann Am Thorac Soc 2021;18(3):502-510. PubMed
  29. Nan X, Lu H, Wu J, et al. The interactive association between sodium intake, alcohol consumption and hypertension among elderly in northern China: a cross-sectional study. BMC Geriatr 2021;21(1):135. PubMed
  30. Kyozuka H, Fukusda T, Murata T, et al. Impact of preconception sodium intake on hypertensive disorders of pregnancy: The Japan Environment and Children's study. Pregnancy Hypertens 2021;23:66-72. PubMed
  31. Zhao L, Ogden CL, Yang Q, et al. Association of usual sodium intake with obesity among US children and adolescents, NHANES 2009-2016. Obesity (Silver Spring) 2021;29(3):587-594. PubMed
  32. Ma Y, He FJ, Sun Q, et al. 24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med 2022;386(3):252-263. PubMed
  33. Liu J, Yang X, Zhang P, et al. Association of urinary sodium excretion and left ventricular hypertrophy in people with type 2 diabetes mellitus: A cross-sectional study. Front Endocrinol (Lausanne) 2021;12:728493. PubMed
  34. Filippini T, Malavolti M, Whelton PK, Vinceti M. Sodium intake and risk of hypertension: A systematic review and dose-response meta-analysis of observational cohort studies. Curr Hypertens Rep 2022;24(5):133-144. PubMed
  35. Wang DD, Li Y, Nguyen XT, et al. Dietary sodium and potassium intake and risk of non-fatal cardiovascular diseases: The million veteran program. Nutrients 2022;14(5):1121. PubMed
  36. Kwak JH, Park CH, Eun CS, et al. The associations of dietary intake of high sodium and low zinc with gastric cancer mortality: A prospective cohort study in Korea. Nutr Cancer 2022;74(10):3501-3508. PubMed
  37. George S, Maiti R, Mishra BR, Jena M, Mohapatra D. Effect of regulated add-on sodium chloride intake on stabilization of serum lithium concentration in bipolar disorder: A randomized controlled trial. Bipolar Disord 2023;25(1):66-75. PubMed
  38. Zhou TL, Schütten MTJ, Kroon AA, et al. Urinary Sodium Excretion and Salt Intake Are Not Associated With Blood Pressure Variability in a White General Population. J Am Heart Assoc 2023;12(1):e026578. PubMed

See these in context on the Sodium monograph →

Lecithin 9 references
  1. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-70.
  2. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: http://b
  3. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 1990;300:495-9.
  4. Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-53.
  5. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:736-42. PubMed
  6. Palm M, Moneret-Vautrin DA, Kanny G, et al. Food allergy to egg and soy lecithins. Allergy 1999;54:1116-7. PubMed
  7. Drachman DA, Glosser G, Fleming P, et al. Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 1982;32:944-50. PubMed
  8. Gelenberg, A. J., Doller-Wojcik, J. C., and Growdon, J. H. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry 1979;136(6):772-776. PubMed
  9. Electronic Code of Federal Regulations. Title 21, Chapter 1, Subchapter B, Part 184: Direct food substances affirmed as Generally Recognized as Safe. Subpart B - listing of specific substances affirmed as GRAS. Sec. 184.1400 Lecithin. Available at: https:

See these in context on the Lecithin monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring